^
    Back
    Association details:
    Biomarker:HER-2 C634R
    Cancer:HER2 Positive Breast Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2018
    Title:

    Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.

    Published date:
    05/16/2018
    Excerpt:
    There were three cases identified where HER2 mutation status impacted the selection of personalized anti-HER2 therapies….Case 1 was a HER2 positive patient with an ERBB2 mutation (c.1900T>C/p.C634R) who was resistant to trastuzumab and lapatinib but sensitive to afatinib.
    DOI:
    10.1200/JCO.2018.36.15_suppl.1039